UPDATE 1-Novartis CAR-T therapy leads to durable response in lymphoma study

Dec 10 (Reuters) - Patients with an advanced form of an aggressive blood cancer who had initially responded to Novartis' new type of gene-modifying immunotherapy continued to respond at least six months after treatment, according to updated data released at a medical meeting on Sunday.